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Background: Obstructive sleep apnea (OSA) is emerging as a significant disorder in India. Tumor
necrosis factor-a (TNFa) is an important marker of inflammation. Recent data indicate that
inflammation may be an important correlate of OSA. The relationships of OSA with TNFa levels
and TNFa gene promoter polymorphism (308G/A) have not been investigated in obese Asian
Indians with OSA.
Objective: To look for the correlation if any, between TNFa gene promoter polymorphism
(308G/A) in obese Asian Indians with and without OSA and correlation of TNFa levels with
severity of OSA.
Methods and results: We studied 207 obese (BMI> 25 kg/m2) subjects; 104 with OSA and 103
without OSA. Both groups were matched for age, body mass index (BMI) and percentage body
fat (%BF). Measurements included anthropometric and biochemical (fasting blood glucose,
lipid profile and serum TNFa levels) parameters and TNFa gene promoter polymorphism
(308G/A). The frequency of ‘308A’ allele in TNFa gene was significantly higher in obese
subjects with OSA (28.8%; 60/208), when compared with obese subjects without OSA (12.6%;
26/206, pZ 0.001). Serum TNFa levels were significantly higher in obese subjects with OSA
[(3.6  0.8)pg/ml], when compared with obese subjects without OSA [(3.3  0.6)pg/ml,
pZ 0.009].med: All India Institute of Medical Sciences, New Delhi, India
l medicine and basic science: This study provides important information regarding TNFa gene poly-
ians with OSA. These data have potential implications for future genotyping of Asian Indians with OSA
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Genetics of OSA in Asian Indians 387Conclusions: Frequency of TNFa (308A) allele and serum TNFa level was significantly higher
in obese Asian Indians with OSA.
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Obstructive sleep apnea (OSA) is a disorder characterized
by repetitive collapse of upper airway during sleep. It
affects about 4e9% of adult population and children.1
Prevalence of OSA is 7.5% in Asian Indians living in India.2
OSA is now considered as an independent risk factor for
hypertension and cardiovascular mortality.3,4 There is
increasing evidence that OSA is associated with inflamma-
tion. TNFa (308G/A) polymorphism is associated with
increased TNFa levels.5,6 Derangements of inflammatory
cytokines, such as C-reactive protein (CRP) and interleukin-
6 (IL-6) have been reported in OSA.7,8 Tumor necrosis
factor-a (TNFa), a pro-inflammatory cytokine may have
a role in regulation of sleep.9,10 Excessive daytime sleepi-
ness (EDS), a major feature of OSA, is promoted by increase
in TNFa levels.7,9 Ryan et al. have shown that intermittent
hypoxia is a strong predictor of serum TNFa levels.11
The primary risk factor for OSA is excessive weight gain.
Other than male gender, obesity is the strongest risk factor
for the development of OSA.12,13 Various studies indicate
that about 66% of patients with OSA are obese. Significant
weight loss has been shown to have varying degrees of
improvement in OSA.14 Previous studies on Asian Indians
with OSA are limited to assessment of prevalence data,
evaluation of relationship of OSA with road traffic accidents
and public health awareness of OSA.2,15,16 Data regarding
relationship of sub-clinical inflammation and OSA are
limited. Recently, we have shown the association of
severity in OSA with increasing levels of CRP in obese Asian
Indians.17 The relationship of TNFa levels and its promoter
polymorphism (308G/A) has not been investigated in
Asian Indians with OSA. Since high levels of TNFa have been
linked to EDS,11 it is possible that TNFa (308G/A)
promoter polymorphism may associate with the develop-
ment of OSA in obese Asian Indians with OSA.
We conducted this cross-sectional study to determine
the frequency of TNFa (308A) allele in obese subjects
with and without OSA. Correlation, if any, of serum TNFa
levels with OSA severity was also looked at in these obese
subjects.
Methods
Subjects
A total of 207 obese subjects were recruited from Medicine
out patients department of All India Institute of Medical
Sciences, a tertiary care referral hospital. The subjects were
North Indians residing in New Delhi or surrounding areas
located near New Delhi. 104 obese subjects were newly
diagnosed with OSA (84 males and 20 females) and 103 obese
subjects were without OSA (65 males and 38 females). To
nullify theeffect of obesity, subjectswerecarefullymatched
for age, body mass index (BMI) and percentage body fat(%BF). Full montage polysomnography (PSG) was performed
in all subjects. On the basis of apnea-hypopnea index (AHI),
subjects were categorized as with or without OSA (see defi-
nitions below). All subjects were free of any acute or
apparent chronic inflammatory disorders, chronic obstruc-
tive pulmonary disease (COPD) and coronary heart disease
(CHD; based on clinical history and ECG). Subjects with other
sleep disorders such as upper airway resistance syndrome
(UARS), central sleep apnea (CSA), periodic limbs movement
(PLMs) or narcolepsy were excluded. All subjects were non-
smokers or had quit smoking before three years. No subject
was takinganymedications at the timeofevaluation. Clinical
evaluation for all subjects included thyroid profile and an
ECG was done on enrollment. The study was approved by
institutional ethics committee andwritten informed consent
was obtained from all subjects.
Metabolic parameters
Blood samples were collected after an overnight fast for
estimation of fasting blood glucose (FBG) and blood lipo-
proteins. Levels of FBG, total cholesterol (TC) and serum
triglycerides (TG) were estimated using commercial kits
(Randox Laboratory, San Francisco, CA, USA) in a semi-
automated analyzer (Micro Semi-Autoanalyser 2000, C.L.
Micromed, Italy).
Anthropometric measurements
The anthropometric measurements were carried out by
a physician according to methods described earlier.18
Briefly, waist circumference was measured midway
between the highest point of superior iliac crest and lowest
point of costal margin; hip circumference was measured at
the maximum circumference of buttocks. All measurements
were taken in standing position with feet placed together.
Measurement of % BF was carried out using leg-to-leg (two
point contact) bioelectrical impedance method (Tanita TBF
300, TANITA Corp., Tokyo, Japan). For estimation of
bioelectrical impedance, subjects were evaluated after an
overnight fast. They were instructed to avoid fluid intake
and void urine 1 h prior to measurements and just before
the test. Gender and height details were manually entered
into the system. Subjects were instructed to stand on
apparatus so that both feet were in firm contact with the
surface of apparatus and hands were not in touch with any
surface.
Polysomnography (PSG)
All subjects underwent overnight digital full montage PSG
(Medi palm; Braebon Medical Corp., Canada) and classified
according to AHI (see definitions). Digital PSG included elec-
trooculogram, electroencephalogram, electromyogram,
electrocardiogram, airflow (with an oro-nasal thermistor),
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saturation by pulse oximeter. The recordings were done using
pursuit recording device and studies were analyzed at 30 s
epochs. Sleep study analysis and sleep stages were scored
according to standard criteria of Rechtschaffen and Kales
manual.19,20 Obstructive apneas and hypopneas were typi-
cally distinguished from central events by detection of
respiratory efforts during event.
Definitions
Obesity was defined as BMI> 25 kg/m221 and morbid obesity
was defined as BMI> 40 kg/m2.22 Diagnosis of OSA was
made on the basis of international classification of sleep
disorders.23 Breathing event was defined according to the
commonly used clinical criteria published by American
Academy of Sleep Medicine Task Force.20 Apnea was
defined as cessation of airflow 10 s. Hypopnea was
defined as recognizable, transient reduction of breath-
ing 10 s associated with either an oxygen desaturation of
4% or an arousal. AHI was defined as number of obstruc-
tive apneas and hypopneas per hour of sleep. Subjects with
an AHI< 5/h were assigned as not having OSA and subjects
with an AHI 10/h were diagnosed to have OSA. Subjects
having AHI between 5 and 10/h were not included in the
analysis to maintain a clear distinction between subjects
with and without OSA. Subjects having OSA were further
classified as mild (AHI 10e15/h), moderate (AHI 15e30/h)
and severe (AHI> 30/h) OSA. Epworth sleepiness scale
(ESS) was used to check excessive sleepiness.24 A total
score of less than 10 suggested that a person was not
suffering from excessive sleepiness. ESS greater than or
equal to 10 was used to make the diagnosis of OSA.
Serum TNFa levels
Blood samples for estimating serum levels of TNFa were
collected in the morning between 8 am and 9 am in all
subjects. Serum TNFa levels in all subjects were measured
by enzyme-linked immunosorbent assay (ELISA) based kits
and according to the manufacturers’ instructions (eBio-
sciences, San Diego, CA). The sensitivity range of the kit is
from 4 to 500 pg/ml. The intra-assay variation was 2.0e
2.5% and inter-assay variation was 3e3.5%.
TNFa promoter polymorphism (308G/A)
Venous blood sample (10 ml) was drawn into EDTA con-
taining tubes for DNA isolation. Genomic DNA was extracted
from leucocytes after lysing erythrocytes from cell pellet.
DNA was liberated by sodium dodecyl sulphate (SDS) and
proteinase-K after overnight digestion at 37 C.25 Proteins
were removed by addition of 5 M NaCl, and DNA was
recovered by ethanol precipitation.
The polymorphic variants of TNFa gene promoter region
(308G/A) were determined by polymerase chain reac-
tionerestriction fragment length polymorphism (PCRe
RFLP). The upstream primer sequence was 50AGGCAA
TAGGTTTTGAGGGCCAT30 and downstream primer sequence
was 50TCCTCCCTGCTCCGATTCCG30. The reaction was
carried out in a final volume of 25 ml containing 0.25 mM ofeach dNTP (Bangalore Genei, India), 0.1 mmol of each
primer and 1.25 U of Taq DNA polymerase (Bangalore
Genei, India). DNA was amplified during 35 cycles with
1 min denaturation at 94 C, 1 min annealing at 60 C and
1 min extension at 72 C. Initially, 1 cycle of denaturation
at 94 C, 1 min annealing at 60 C and 1 min extension at
72 C was performed. Finally, a cycle of 1 min denaturation
at 94 C, 1 min annealing at 60 C and 5 min extension at
72 C was included. The PCR product was digested with
0.5 ml of NcoI restriction enzyme (New England Biolabs).
After restriction digestion, three bands of different sizes
were obtained. 107 bp fragment corresponding to variant
allele (Restriction site absent) and a set of 87 bp and 20 bp
corresponding to wild type allele (Restriction site present).
Band pattern was checked by using 10% native poly-
acrylamide gel electrophoresis (PAGE) followed by silver
staining.
Statistical methods
Data were managed using an Excel spreadsheet (Microsoft
Corp., Washington, USA). Mean and standard deviation
(S.D.) are used as summary measures. Due to high range of
TNFa levels in samples, values are expressed as Log values.
Student’s ‘t’ test was applied using parametric method to
compare mean values between subjects with and without
OSA. In case of high standard deviation, nonparametric test
was used. ANOVA, followed by multiple comparisons (post
hoc test) was used to compare mean values of parameters
between subjects without OSA and subjects with various
levels in severity of OSA. Multiple logistic regression anal-
ysis was done to check the effect of gender and other
variables on TNFa levels. Power of the study was deter-
mined using STATA statistical software. The HardyeWein-
berg equilibrium was tested by using (p2þ 2pqþq2Z 1)
formula. SPSS (Chicago, version 15) statistical software was
used for data analysis and p< 0.05 was considered as
statistically significant.
Results
Table 1 shows characteristics and TNFa levels of subjects
with and without OSA. There was no significant difference
in the mean values of age, BMI, %BF, waist circumference
and hip circumference in these groups. The mean values of
neck circumference, calf circumference, diastolic blood
pressure, FBG levels and the blood glucose levels 2-h after
75 g oral glucose load were significantly higher in subjects
with OSA, when compared with subjects without OSA.
There was no significant difference in total cholesterol (TC)
and triglyceride (TG) levels in subjects with and without
OSA. Serum TNFa levels were significantly higher in
subjects with OSA as compared to subjects without OSA.
Table 2 shows the ESS and polysomnography profile of
subjects with and without OSA. The frequency of TNFa
(308A) allele was significantly higher in obese subjects
with OSA (28.8%), when compared with obese subjects
without OSA (12.6%; pZ 0.001; Table 3).
Subjects with OSA having TNFa (308G/A) genotype had
a significantly higher AHI [median (range)] [63.7 (10.8e
87.4)/h vs. 28.4 (10.2e121.2)/h; pZ 0.007], serum TNFa
Table 1 Characteristics of obese subjects with and without OSA.
Variables Subjects with
OSA (nZ 104)
Subjects without
OSA (nZ 103)
p-Value OR (95% CI)
Sex ratio M:F 84:20 65:38 0.005
Age (y) 46.18 10.7 44.0 10.0 0.14 1.0 (0.9e1.0)
BMI (kg/m2) 31.48 4.26 30.94 4.27 0.36 1.0 (0.9e1.1)
Anthropometry
% BF 37.1 10.7 36.51 9.89 0.71 1.0 (0.9e1.0)
WC (cm) 105.0 7.3 102.8 7.8 0.06 1.0 (0.9e1.0)
NC (cm) 39.6 4.4 37.9 3.1 0.003 1.1 (1.0e1.2)
HC (cm) 103.4 9.0 100.9 8.7 0.06 1.0 (0.9e1.0)
CC (cm) 38.6 3.4 35.8 3.1 0.001 1.3 (1.1e1.4)
Blood glucose during OGTT (mg/dl)
FBG 113.6 23.3 104.5 20.1 0.006 1.0 (1.0e1.0)
2-h BG 155.6 44.6 138.1 36.7 0.008 1.0 (1.0e1.0)
Lipid profile (mg/dl)
TC 194.2 42.2 188.9 36.4 0.38 1.0 (0.9e1.0)
TG 170 71.1 160.1 50.1 0.29 1.0 (0.9e1.0)
HDL-C 44.6 6.0 44.35 4.9 0.97 1.0 (0.9e1.0)
Blood pressure (mmHg)
Systolic 135.3 16.2 132.6 17.9 0.30 1.0 (0.9e1.0)
Diastolic 89.6 11.1 85.7 10.9 0.02 1.0 (1.0e1.0)
Log TNFa level (pg/ml) 3.6 0.8 3.3 0.6 0.009 1.6 (1.1e2.4)
M, male; F, female; BMI, body mass index; RPR, resting pulse rate; %BF, percentage body fat; WC, waist circumference; NC, neck
circumference; HC, hip circumference; CC, calf circumference; FBG, fasting blood glucose; 2-h BG, 2-h blood glucose after oral glucose
load; OGTT, oral glucose tolerance test; TC, total cholesterol; TG, triglycerides; HDL-C, high-density lipoproteinecholesterol; TST, total
sleep time; REM, rapid eye movement; ESS, Epworth sleepiness scale; and TNFa, tumor necrosis factor-a. Data presented as mean SD.
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pZ 0.009] and significantly decreased mean SpO2 levels
[(79.4 9.3) vs. (84.6 11.0)%, pZ 0.03], when compared
with subjects with OSA and having TNFa (308G/G)
genotype.
Subjects with OSA having 308G/A genotype were
having significantly high AHI [(54.5 25.3) vs. (29.7 8.9)
y, pZ 0.001], hip circumference [(104.8 3.4) vs.
(99.5 2.2) cms, pZ 0.001] and mean SpO2 levels
[(79.4 9.3) vs. (86.5 4.1) %, pZ 0.008], when comparedTable 2 ESS and polysomnography profiles in subjects
with and without OSA.
Variables Subjects with
OSA (nZ 104)
Subjects without
OSA (nZ 103)
p-Value
TST (h) 6.4 0.9 6.3 0.8 0.40
Sleep latency
(min)
10.2 4.1 25.6 5.2 0.001
Sleep efficiency
(%)
78.5 6.5 87.3 6.6 0.006
REM sleep (%) 11.3 4.0 18.0 4.6 0.008
Mean SpO2 (%) 83.6 10.5 96.3 2.4 0.003
Minimum SpO2
(%)
73.4 12.9 94.1 3.5 0.004
ESS 14.7 5.2 8.1 3.4 0.001
TST, total sleep time; REM, rapid eye movement; and ESS,
Epworth sleepiness scale. Data presented as mean SD.with subjects with OSA having 308A/A genotype. There
was no significant difference in TNFa levels in subjects with
OSA having 308G/A genotype [(4.4 0.8) pg/ml], when
compared with subjects with OSA having 308A/A geno-
type [(3.8 0.9) pg/ml, pZ 0.12].
Subjects with OSA having TNFa (308A) allele were
having a significantly higher value of waist circumference,
neck circumference, systolic blood pressure,mean SpO2, ESS
and TNFa levels when compared with subjects without OSA
havingTNFa (308A) allele.Mean levels of TC, TG andHDL-C
were comparable between these two groups (Table 4).
Morbid obese subjects with OSA (nZ 5) were having AHI
[(50.7 12.3)/h], mean SpO2 [(73.7 15.6) %] and serum
TNFa levels [(3.5 0.86) pg/ml]. As the number of morbidTable 3 Genotype and allelic frequencies for
TNFa(308G/A) polymorphism in subjects with and without
OSA.
Variable Subjects with
OSA (nZ 104)
Subject without
OSA (nZ 103)
p-Value
GG 74 (71.1) 90 (87.4) 0.008
GA 22 (21.2) 10 (9.7)
AA 8 (7.7) 3 (2.9)
G 192 (92.3) 200 (97.0) 0.005
A 60 (28.8) 26 (12.6) 0.001
Data presented as n(%), unless otherwise stated.
Table 4 Comparison of baseline, anthropometric and lipid profile in subjects having TNFa (308A) allele.
Variables Subjects with OSA
having (308A) allele
(nZ 30)
Subjects without OSA
having (308A) allele
(nZ 13)
p-Value
AHI (per h) 47.9 24.6 2.8 1.7 0.001
BMI (kg/m2) 31.0 3.8 29.2 3.6 0.15
%BF 39.1 9.6 37.1 9.0 0.55
WC (cm) 105.1 7.4 98.9 7.9 0.03
NC (cm) 39.8 3.2 37.2 2.6 0.01
FBG (mg/dl) 112.9 18.6 101.0 8.1 0.01
2 h-BG (mg/dl) 161.3 35.4 132.1 21.8 0.009
SBP (mmHg) 136.1 15.7 125.0 13.9 0.04
DBP (mmHg) 91.1 10.0 86.0 9.2 0.14
Mean SpO2 (%) 81.3 8.8 96.1 2.6 0.001
Log TNFa levels (pg/ml) 4.2 0.8 3.6 0.6 0.04
AHI, apnea hypopnea index; BMI, body mass index; %BF, percentage body fat; WC, waist circumference; NC, neck circumference; HC, hip
circumference; FBG, fasting blood glucose; 2-h BG, 2-hours blood glucose after 75 g oral glucose load; OGTT, oral glucose tolerance test;
SBP, systolic blood pressure; and DBP, diastolic blood pressure. p-value for AHI was calculated by nonparametric test. Other p-values
were calculated by parametric Student’s ‘t’ test. Data are expressed as mean S.D.
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compared with those not coming in morbid obese category.
Subjects with mild, moderate and severe OSA had
significantly higher calf circumference, when compared
with subjects without OSA. Subjects with severe OSA had
significantly higher diastolic blood pressure, neck circum-
ference, hip circumference, calf circumference and 2-h
blood glucose, with respect to subjects without OSA group.
Subjects with severe OSA were having significantly high
serum TNFa levels [(3.8 0.9) pg/ml] as compared to
subjects with mild OSA [(3.3 0.6) pg/ml, pZ 0.005] and
subjects without OSA [(3.3 0.6) pg/ml, pZ 0.001].
Logistic regression analysis was done by adjusting for
FBG, 2 h-BG and diastolic blood pressure variables. It
showed that TNFa (308A) allele frequency and TNFa
levels were higher in subjects with OSA [OR (95% CI)
2.1(1.2e3.7), pZ 0.008 and 1.6(1.1e2.4), pZ 0.009
respectively]. It was also found that gender difference was
not a confounding factor for increased TNFa levels in these
subjects [1.0(0.9e1.0); pZ 0.14)].Discussion
This study is the first attempt to look at the TNFa gene
promoter polymorphism (308G/A) and relationship of
severity in OSA with serum TNFa levels in obese Asian
Indians with OSA. In Indian context, previous studies on
TNFa levels and its gene polymorphism have been
conducted in diabetes, asthma and inflammatory bowel
disease.26e28 Our study shows that, even after excluding
effects of age, BMI and %BF, subjects with OSA have
significantly higher serum TNFa levels, when compared
with those without OSA. Furthermore, increase in serum
TNFa levels demonstrated a stepwise increase with severity
of OSA.
Significant increase in AHI, TNFa levels and significant
decrease in SpO2 levels in subjects with OSA having ‘308A’
allele than ‘308G’ allele suggests that TNFa (308A)
allele may be a risk factor for OSA in these subjects.Two previous studies have looked at TNFa gene poly-
morphism in OSA subjects.29,30 Riha et al. (2005) reported
an association of TNFa gene polymorphism (308A)
carriage with obstructive sleep apnea in 206 subjects in
UK.29 Serum levels of TNFa were not measured in this study.
Liu et al. (2006), in a small study (nZ 18) reported that
plasma levels of TNFa were significantly higher in Chinese
subjects having OSA, when compared with controls.30 These
authors opined that TNFa gene (308A) allele might lead to
susceptibility for OSA. In the present study, the frequency
of TNFa gene (308A) allele was twice as high in subjects
with OSA, when compared with those without OSA, sug-
gesting that this gene polymorphism may increase the risk
of inflammation in these obese Asian Indians with OSA.
However, these data need to be evaluated in a larger
number of subjects.
TNFa acts through nuclear factor kappa-B (NF Kappa B)
pathway and a recent study shows that NF Kappa B acti-
vation occurs in OSA, which in turn may contribute to
pathogenesis of atherosclerosis, frequently seen in
subjects with OSA.11,31,32 TNFa has been found to be
a direct mediator of inflammation in atherosclerotic
lesions.33 Serum levels of TNFa and of other inflammatory
markers like Interlukin-6 (IL-6) and CRP correlate signifi-
cantly with common carotid intima-media thickness (IMT)
in healthy subjects, indicating association with early
atherosclerosis.34,35
Asian Indians are highly predisposed to develop CHD due
to multiple factors.36 To this list, OSA may now be added,
particularly in view of our data showing high levels of TNFa
in these subjects. It is important to note that TNFa levels
have been found to be a predictor of incident cardiovas-
cular events and all-cause mortality.37 Whether, high serum
levels of TNFa in obese Asian Indians with OSA accurately
predict and contribute to increase cardiovascular risk needs
to be investigated in prospective studies.
Whether TNFa level is involved in pathogenesis of OSA or
is a result of physiological disturbances due to OSA is not
clearly known. However, mechanisms linking increase in
levels of serum TNFa in OSA subjects may probably include
Genetics of OSA in Asian Indians 391repetitive hypoxemic stress and sleep deprivation.7 Also,
intermittent hypoxia, a major characteristic of OSA, has
been reported to be the strongest predictor of TNFa
levels.7
The present study shows that obese subjects with OSA
have significantly higher frequency of TNFa (308A) allele
and TNFa levels correlate with the severity of OSA. Few
studies suggest sexual dimorphism in TNFa levels.38 Logistic
regression analysis suggested that raised TNFa levels in our
study were not due to gender difference.
Population stratification may be responsible for
observed association of TNFa 308A allele with OSA.
Genotype frequencies of obese subjects without OSA were
in HardyeWeinberg equilibrium, justifying against error by
population stratification. Previous studies suggest that in
association studies, population stratification can be
detected by using unlinked genetic markers.39 We studied
two polymorphisms (Apolipoprotein E, E2, E3, E4 and
Neuropeptide Y; Leu7Pro) for association with OSA. These
genes are not known to be in linkage disequilibrium with
TNFa gene. We did not find their increased frequency in
subjects with OSA and their genotypic distributions were in
HardyeWeinberg equilibrium. The numbers of markers
studied were not sufficient to perform the population
stratification test. Few studies have also shown that error
rate by population stratification is very small in such
epidemiological studies.40,41 Power of the study was 73.7%
in allelic frequency and 100% power was obtained in serum
TNFa level and AHI.
Logistic regression analysis suggested that gender
difference was not a confounding factor; however, the calf
circumference, 2 h-BG and serum TNFa levels were found
to be confounding factors for OSA in these subjects. These
findings suggest that the raised TNFa levels were not by
chance and were linked with OSA.
There are certain limitations of our study. We did not
have the data on siblings and other ancestral members of
these subjects to detect the exact effect of population
stratification. We were not having the data on other pop-
ulation controls as well. Clinically it is suggested to find out
a marker linked with increased risk of OSA (e.g. cardio-
vascular diseases). We restricted the recruitment of study
subjects to obese with and without OSA and excluded
subjects with other diseases to see an independent effect
of TNFa levels on OSA. The strength of the present study is
that, to nullify the effect of obesity, subjects were care-
fully matched for BMI and %BF. All subjects were studied in
the same sleep laboratory and sleep study analysis was
done by single expert using standard analysis instructions.
Further, subjects were carefully selected to avoid effect of
any apparent acute or chronic inflammatory disease or
infections.
Finally, more research questions based on our data
need answers. There are evidences that TNFa level
decreases after treatment of OSA with continuous positive
airway pressure (CPAP).42 For instance, whether treatment
of OSA in our subjects with CPAP will lead to decrease in
serum TNFa levels needs to be investigated. The effect of
interventions such as weight loss and new therapies of
metabolic syndrome (e.g. endocannabinoid receptor-1
blocker, Rimonabant) on TNFa levels needs to be investi-
gated. Finally TNFa (308G/A) polymorphism should beinvestigated as candidate gene polymorphism for OSA in
other ethnic groups.
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